ZEALAND PHARMA/S (ZEAL) Receives Average Rating of “Buy” from Brokerages
Shares of ZEALAND PHARMA/S (NASDAQ:ZEAL) have been given a consensus rating of “Buy” by the seven ratings firms that are currently covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $29.00.
A number of brokerages recently issued reports on ZEAL. Zacks Investment Research downgraded ZEALAND PHARMA/S from a “buy” rating to a “hold” rating and set a $21.00 price objective for the company. in a research report on Saturday, April 13th. Needham & Company LLC restated a “buy” rating and set a $29.00 target price on shares of ZEALAND PHARMA/S in a report on Thursday, March 7th. TheStreet upgraded ZEALAND PHARMA/S from a “d+” rating to a “c-” rating in a report on Tuesday, January 22nd. Finally, ValuEngine upgraded ZEALAND PHARMA/S from a “sell” rating to a “hold” rating in a report on Friday, March 15th.
An institutional investor recently bought a new position in ZEALAND PHARMA/S stock. OLD Mission Capital LLC purchased a new stake in shares of ZEALAND PHARMA/S (NASDAQ:ZEAL) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 17,466 shares of the company’s stock, valued at approximately $203,000. OLD Mission Capital LLC owned 0.06% of ZEALAND PHARMA/S as of its most recent filing with the Securities and Exchange Commission. 9.23% of the stock is currently owned by institutional investors.
ZEALAND PHARMA/S (NASDAQ:ZEAL) last issued its earnings results on Thursday, May 16th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.45). On average, equities analysts expect that ZEALAND PHARMA/S will post -1.68 EPS for the current year.
ZEALAND PHARMA/S Company Profile
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.
Further Reading: Elliott Wave Theory
Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.